Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 4, 2007, Pages 577-584

  Neo, Jaclyn H ^a   Malcontenti Wilson, Cathy ^a   Muralidharan, Vijayaragavan ^a   Christophi, Christopher ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ACE inhibitors; Angiogenesis; Angiotensin II receptor antagonist; Liver metastases; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; RESIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; LIVER HISTOLOGY; LIVER METASTASIS; MALE; MICROCIRCULATION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEREOLOGY; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VASCULARIZATION;

EID: 33947199851     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04797.x     Document Type: Article

References (23)

1. Stoeltzing O, Liu W, Reinmuth N et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann. Surg. Oncol. 2003; 10: 722-33.
2. World Health Organisation (WHO). Global Cancer Rates Could Increase by 50% to 15 Million by 2020 [Press Release]. Geneva: WHO, 2003. Available from URL: http://www.who.int/mediacentre/news/releases/2003/pr27/en/print.html
3. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2001 (Cancer Series no. 28). Canberra: AIHW, 2004. Available from URL: http://www.aihw.gov.au/publications/can/ca01/ca01.pdf
4. Kuruppu D, Christophi C, Bertram JF, O'Brien PE. Characterization of an animal model of hepatic metastasis. J. Gastroenterol. Hepatol. 1996; 11: 26-32.
5. Anastasopoulos F, Leung R, Athena K et al. Marked difference between angiotensin-converting enzyme and neutral endopeptidase in vivo by a dual inhibitor of both enzymes. J. Pharmacol. Exp. Ther. 1997; 284: 799-805.
6. Leenen FHH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 2001; 37: 981-4.
7. Imai K, Hayashi Y, Hashimoto K. [Acute toxicological studies of captopril in rats and mice.] J. Toxicol. Sci. 1981; 6 (Suppl. 2): 179-88 (in Japanese).
8. Bristol-Myers Squibb. Avalide (Irbesartan-hydrochlorothiazide) Tablets. New York: Bristol-Myers Squibb, 2005. Available from URL: http://www.bms.com/cgi-bin/anybin.pl?sql= select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=57&key=PPI
9. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin. Cancer Res. 2001; 7: 1052-60.
10. Kuruppu D, Christophi C, O'Brien PE. Microvascular architecture of hepatic metastases in a mouse model. HPB Surg. 1997; 10: 149-57;discussion 158.
11. Yoshiji H, Kuriyama S, Kawata M et al. The angiotensin-I- converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001; 7: 1073-8.
12. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor et al. growth and angiogenesis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 2004; 130: 567-73.
13. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 1999; 5: 1359-64.
14. Noguchi R, Yoshiji H, Kuriyama S et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 2003; 9: 6038-45.
15. Volpert OV, Ward WF, Lingen MW et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996; 98: 671-9.
16. Boedefeld WM 2nd, Bland KI, Heslin MJ. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann. Surg. Oncol. 2003; 10: 839-51.
17. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 1993; 44: 1266-72.
18. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001; 495: 197-200.
19. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem. Biophys. Res. Commun. 2002; 294: 441-7.
20. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002; 62: 4176-9.
21. Uemura H, Ishiguro H, Nakaigawa N et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003; 2: 1139-47.
22. Lever AF, Hole DJ, Gillis CR et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
23. Ronquist G, Rodriguez LA, Ruigomez A et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58: 50-6.